Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy.
- Author:
Ki Hyun KIM
1
;
Hyori KIM
Author Information
- Publication Type:Review
- MeSH: Antibodies; Carcinogenesis; Drug Resistance; Hepatocyte Growth Factor; Humans; Neoplasm Metastasis; Protein-Tyrosine Kinases
- From:Experimental & Molecular Medicine 2017;49(3):e307-
- CountryRepublic of Korea
- Language:English
- Abstract: Dysregulated receptor tyrosine kinase signaling in human cancer cells leads to tumor progression, invasion and metastasis. The receptor tyrosine kinase cMET is frequently overexpressed in cancer tissue, and activation of cMET signaling is related to drug resistance and the processes of carcinogenesis, invasion and metastasis. For that reason, cMET and its ligand, hepatocyte growth factor (HGF), are considered prime targets for the development of anticancer drugs. At least eight anti-cMET and four anti-HGF antibodies have been tested or are being tested in clinical trials. However, to date none of these HGF/cMET inhibitors have shown significant efficacy in clinical trials. Furthermore, no receptor tyrosine kinase inhibitors primarily targeting cMET have been approved. Given that neutralization of HGF or cMET does not cause significant adverse effects, inhibition of the HGF/cMET signaling pathway appears to be safe. In this review, we summarized the completed and ongoing clinical trials testing antibody- or protein-based anticancer drugs targeting cMET and HGF.
